A strategic framework for novel drug development in multiple myeloma

Br J Haematol. 2007 Jul;138(2):153-9. doi: 10.1111/j.1365-2141.2007.06641.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / analysis
  • Clinical Trials, Phase I as Topic / methods
  • Clinical Trials, Phase II as Topic / methods
  • Clinical Trials, Phase III as Topic / methods
  • Drug Therapy, Combination
  • Humans
  • Multiple Myeloma / drug therapy*
  • Patient Selection
  • Randomized Controlled Trials as Topic / methods
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor